177 related articles for article (PubMed ID: 19963382)
1. Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423.
Evelyn CR; Bell JL; Ryu JG; Wade SM; Kocab A; Harzdorf NL; Showalter HD; Neubig RR; Larsen SD
Bioorg Med Chem Lett; 2010 Jan; 20(2):665-72. PubMed ID: 19963382
[TBL] [Abstract][Full Text] [Related]
2. Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents.
Bell JL; Haak AJ; Wade SM; Kirchhoff PD; Neubig RR; Larsen SD
Bioorg Med Chem Lett; 2013 Jul; 23(13):3826-32. PubMed ID: 23707258
[TBL] [Abstract][Full Text] [Related]
3. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.
Evelyn CR; Wade SM; Wang Q; Wu M; Iñiguez-Lluhí JA; Merajver SD; Neubig RR
Mol Cancer Ther; 2007 Aug; 6(8):2249-60. PubMed ID: 17699722
[TBL] [Abstract][Full Text] [Related]
4. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
5. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.
Johnson LA; Rodansky ES; Haak AJ; Larsen SD; Neubig RR; Higgins PD
Inflamm Bowel Dis; 2014 Jan; 20(1):154-65. PubMed ID: 24280883
[TBL] [Abstract][Full Text] [Related]
6. RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling.
Hayashi K; Watanabe B; Nakagawa Y; Minami S; Morita T
PLoS One; 2014; 9(2):e89016. PubMed ID: 24558465
[TBL] [Abstract][Full Text] [Related]
7. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes.
Cen B; Selvaraj A; Burgess RC; Hitzler JK; Ma Z; Morris SW; Prywes R
Mol Cell Biol; 2003 Sep; 23(18):6597-608. PubMed ID: 12944485
[TBL] [Abstract][Full Text] [Related]
8. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
[TBL] [Abstract][Full Text] [Related]
9. Induction of megakaryocyte differentiation drives nuclear accumulation and transcriptional function of MKL1 via actin polymerization and RhoA activation.
Smith EC; Teixeira AM; Chen RC; Wang L; Gao Y; Hahn KL; Krause DS
Blood; 2013 Feb; 121(7):1094-101. PubMed ID: 23243284
[TBL] [Abstract][Full Text] [Related]
10. Stereospecific Inhibitory Effects of CCG-1423 on the Cellular Events Mediated by Myocardin-Related Transcription Factor A.
Watanabe B; Minami S; Ishida H; Yoshioka R; Nakagawa Y; Morita T; Hayashi K
PLoS One; 2015; 10(8):e0136242. PubMed ID: 26295164
[TBL] [Abstract][Full Text] [Related]
11. A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.
Rahim S; Minas T; Hong SH; Justvig S; Çelik H; Kont YS; Han J; Kallarakal AT; Kong Y; Rudek MA; Brown ML; Kallakury B; Toretsky JA; Üren A
PLoS One; 2014; 9(12):e114260. PubMed ID: 25479232
[TBL] [Abstract][Full Text] [Related]
12. The transcriptional coactivators megakaryoblastic leukemia 1/2 mediate the effects of loss of the tumor suppressor deleted in liver cancer 1.
Muehlich S; Hampl V; Khalid S; Singer S; Frank N; Breuhahn K; Gudermann T; Prywes R
Oncogene; 2012 Aug; 31(35):3913-23. PubMed ID: 22139079
[TBL] [Abstract][Full Text] [Related]
13. LMO7 mediates cell-specific activation of the Rho-myocardin-related transcription factor-serum response factor pathway and plays an important role in breast cancer cell migration.
Hu Q; Guo C; Li Y; Aronow BJ; Zhang J
Mol Cell Biol; 2011 Aug; 31(16):3223-40. PubMed ID: 21670154
[TBL] [Abstract][Full Text] [Related]
14. Discovery and optimization of benzenesulfonanilide derivatives as a novel class of 11β-HSD1 inhibitors.
Rew Y; DeGraffenreid M; He X; Jaen JC; McMinn DL; Sun D; Tu H; Ursu S; Powers JP
Bioorg Med Chem Lett; 2012 Jun; 22(11):3786-90. PubMed ID: 22542009
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional activity of megakaryoblastic leukemia 1 (MKL1) is repressed by SUMO modification.
Nakagawa K; Kuzumaki N
Genes Cells; 2005 Aug; 10(8):835-50. PubMed ID: 16098147
[TBL] [Abstract][Full Text] [Related]
16. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity.
Hwang YS; Hodge JC; Sivapurapu N; Lindholm PF
Mol Carcinog; 2006 Jul; 45(7):518-29. PubMed ID: 16402387
[TBL] [Abstract][Full Text] [Related]
17. Increased diacylglycerol kinase ζ expression in human metastatic colon cancer cells augments Rho GTPase activity and contributes to enhanced invasion.
Cai K; Mulatz K; Ard R; Nguyen T; Gee SH
BMC Cancer; 2014 Mar; 14():208. PubMed ID: 24646293
[TBL] [Abstract][Full Text] [Related]
18. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion.
Hodge JC; Bub J; Kaul S; Kajdacsy-Balla A; Lindholm PF
Cancer Res; 2003 Mar; 63(6):1359-64. PubMed ID: 12649199
[TBL] [Abstract][Full Text] [Related]
19. Snail regulates the motility of oral cancer cells via RhoA/Cdc42/p-ERM pathway.
Li YY; Zhou CX; Gao Y
Biochem Biophys Res Commun; 2014 Sep; 452(3):490-6. PubMed ID: 25172658
[TBL] [Abstract][Full Text] [Related]
20. Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2.
Sandbo N; Ngam C; Torr E; Kregel S; Kach J; Dulin N
J Biol Chem; 2013 May; 288(22):15466-73. PubMed ID: 23580645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
